The Lupus Book: A Guide for Patients and Their Families, Third Edition (56 page)

proprionic acid derivatives,
209

nonsteroidal anti-inflammatories,
211;
and

prostaglandin,
148, 209, 264

pregnancy,
247;
and red blood cells,
153;

protein-losing enteropathy,
138

related diseases,
148–49;
renal vein

proteinuria,
146

thrombosis,
149;
specialized treatments,
232–

prothrombin activator complex,
163

33;
and steroids,
223;
treating,
149–50;
and prothrombin time (PT),
66

urogenital system,
145

proton-pump inhibitors,
137, 212, 224

research on lupus: ACR standards,
5–6;
animal

protozoans,
237

research,
32–33;
bimodal survival curve,

psychiatric disorders,
116, 117, 173

259–60;
economic impact of lupus,
252;

psychology,
192, 203

epidemiology of lupus,
256;
future,
261–66;

pulmonary angiograms,
87

on health care delivery,
256;
importance of,

pulmonary edema,
98

3–4;
incidence and prevalence,
11–13;
new

pulmonary emboli,
91–92, 161

drugs,
261–63;
and pregnancy,
249;
research

pulmonary hemorrhages,
92

deficits,
4;
statistics,
11;
survival studies,

pulmonary hypertension.
See
hypertension

255

pulse oximetry,
86–87

reticuloendothelial system (RES),
157

pulse steroids,
221–22

retina,
122

purpura,
70, 75–76, 157

retinoids,
231

review of systems,
59–61

quality of life,
263

rheumatic diseases,
22,
174–75.
See also

quinacrine,
215, 218, 232

rheumatoid arthritis

quinidine,
53

rheumatoid arthritis: antibody response,
31;

quinine,
214

and anti-RNP,
29;
association with lupus,
7;

complications,
90;
distinguishing from

race and lupus,
11, 13, 153, 256

lupus,
174;
genetic factors,
42;
and

radiation therapy,
46.
See also
chemotherapy

inflammation,
78, 175;
and lupus

raloxifene,
241

misdiagnosis,
12;
prevalence,
173

rapamycin,
264

rheumatoid factor,
31, 68

rapeseed oil,
45

rheumatology,
4, 59,
62,
257

rashes,
9, 70, 73

rhupus,
174

Raynaud’s phenomenon: association with

ribonucleic acid (RNA),
29

lupus,
6;
as autoimmune disease,
175;
and

rights of lupus patients,
196

biofeedback,
204;
and cutaneous lupus,
70;

rimantadine,
239

described,
74–75;
and headaches,
110;
and

risedronate,
241

nicotine,
194;
prevalence,
173;
symptoms,

Ropes, Marian,
9–10, 207

113

rosacea,
73

reagin,
159

Rose Bengal staining,
125

rectum,
134

rosemary,
190

red blood cells (erythrocytes),
17,
19, 21,
30,

Ro (SSA) antibodies,
244, 247

65.
See also
anemia

RPR screen,
68

reflex panel,
66

rue,
190

reflux disease,
133, 135

refractory skin disease,
264

sacroiliac joints,
82

regional ileitis,
137

St. John’s Wort,
186,
190

regional myofascial syndrome,
177

sairei-to,
190

Index

[289]

salicylates,
208,
209.
See also
aspirin

Social Security Disability,
252–53, 253–54

salivary glands,
125

sodium salicylates,
208

sarcoidosis,
175

sodium sucralfate,
137

sassafras,
190

soft tissue,
78–82

Schirmer’s test,
125

sore throat,
133

scleroderma: and anti-RNP,
29;
association

Southeimer, Rick,
184

with lupus,
6, 7;
and calcinosis,
81;

spastic colitis,
136

chemical factors,
44–45;
complications,
90;

specialists,
257

diagnosing,
4;
distinguishing from lupus,

spinal fluid,
107, 119

174;
and inflammation,
175;
prevalence,
173;

spleen,
156, 157–58

supplements for,
205

statistics on lupus,
11.
See also
research on

scotomas,
218

lupus

second opinions,
196

stem cell therapy,
265–66

seizures,
105

sterility,
225, 243–44

selective cox-2 antagonists,
209,
212

steroids: adverse reactions to,
168, 202, 204–5,

self-help,
195, 197, 203

223–25;
and antimalarials,
216;
appearance

senna,
190

issues,
196;
blood problems,
157;
dosages,

serotonin boosters,
179, 193, 203

222–23;
and drug-induced lupus,
55;
and

Serra, Junipero,
259

fevers,
63;
future of,
261;
and immune

serum protein electrophoresis,
68

response,
23;
and infections,
238;
and life

sex and lupus,
35, 131–32, 202–3.
See also

expectancy,
255;
and lymphocytes,
233–34;

gender and lupus

nonfluorinated,
220;
preparations of,
221
;

shoulders,
81

and psychosis,
116;
variety of,
220–22;

shrinking lung syndrome,
93

withdrawal,
224

sickle cell anemia,
153

stomach,
134

sight problems,
121–23.
See also
eyes

streptococcus,
99–100

signs,
61.
See also
diagnosis and assessment

stress,
198, 199–200, 222–23

silica / silicone,
44

strokes,
106, 117, 161, 194, 250

Simon, Lee,
262

Strongyloides,
237

single-positron-emission computed tomography

ST segments,
96

(SPECT),
119

subacute bacterial endocarditis,
100

sinus infections,
123

subacute cutaneous lupus erythematosus

Sioux Indians,
13

(SCLE),
41, 70, 71–72, 231.
See also

6-mercaptopurine,
226,
228

discoid lupus erythematosus (DLE)

Sjo¨gren’s syndrome: antimalarials for,
215,

substance abuse,
173

216;
and autoantibodies,
30;
as autoimmune

suldinac,
210

disease,
175;
blood tests for,
67;
and blood

sulfa antibiotics,
240

thickness,
109;
complications,
90;
described,

sulfa derivatives,
50, 206, 258

124–26;
and eye problems,
121;
genetic

sulfasalazine,
50

factors,
41;
and lupus misdiagnosis,
12;
in

sulfonamide-based antibiotics,
50

mothers,
166;
and renal function,
149;
and

sun sensitivity: and antibiotics,
240;
anti-DNA

sexual dysfunction,
132;
and thyroid,
130;

formation,
46;
and antimalarials,
215;
and

and vaginal dryness,
202

drug-induced lupus,
52;
fear of,
197;
and

skeletal structure.
See
musculoskeletal system

immune suppressive therapies,
227;
and

skin,
69–77;
atrophy,
70;
criteria,
5,
7
;

NSAIDs,
210;
polymorphous light eruption,

diagnosis,
61, 62;
disorders,
76, 215;
malar

73;
preventive measures,
183–84;
and

rash,
9, 70, 73;
pigmentation,
73;
refractory

retinoids,
231;
skin damage,
69;
sunscreens

skin disease,
264;
and steroids,
223.
See

listed,
185

also
discoid lupus erythematosus (DLE)

supplements,
45–46, 205, 241,
241

sleeping problems,
111, 192–93, 223

support groups,
xi,
203

slow acetylators,
44, 52

surgery,
181

small intestine,
134

susceptibility to lupus,
13

smoking,
193–94

Swan-Ganz catheter,
93

social issues of lupus,
168

symptoms.
See
diagnosis and assessment

[290]

Index

synovial cysts,
80

tissue malignancies,
173

synovial fluid,
80

T lymphocytes (T cells): abnormalities,
36;

synovium,
78–80,
79

and antibody production,
24,
24
;
and

syphilis,
68, 159, 162–63, 172

biologics,
266;
formation of,
19
;
growth

Systematic Lupus Erythematosus Self-Help

factor,
25;
and immune response,
18–20;

(SLESH) course,
195, 197

receptor genes,
39;
types of,
21

Systemic Lupus Activity Measure (SLAM),

tobacco use,
193–94

262

tolerance, loss of,
38

Systemic Lupus Erythematosus Disease

tolmetin,
210

Activity Index (SLEDAI),
262

topical anti-inflammatories,
212.
See also

systemic lupus erythematosus (SLE).
See

nonsteroidal anti-inflammatory drugs

specific topics such as
diagnosis and

(NSAIDs)

assessment, treatment,
etc.

total lymphoid irradiation (TLI),
234

Systemic Lupus International Coordinating

transcendental meditation,
204

Committee (SLICC),
257

transforming growth factor (TGF),
22,
155

transfusions,
154, 156

tachycardia,
95–96

transient ischemic attacks (TIAs),
109

tacrolimus,
227,
228,
264

transmission of lupus,
47

T’ai chi,
204

transplant anti-rejection drugs,
228

tartrazines,
44, 250

transplants,
233, 243, 260

tea tree oil,
190

transudates,
88, 138

teenagers.
See
adolescents with lupus

trauma associated with lupus,
199–200

teeth,
100, 123–24, 238

treatments for lupus: cognitive therapy,
203–4,

temperature readings,
63

258;
future of,
261–66;
immune ablative

temporomandibular joint (TMJ),
80–81, 123–

therapy,
265–66;
infections,
238;
other

24

options,
230–35;
proactive strategies,
257–

tender points,
176,
177

58;
response measures,
262–63;
stem cell

tendons,
79,
80

therapy,
265–66;
variables,
256.
See also

testosterone,
127, 230

chemotherapy; therapeutic approaches to

tests for lupus.
See
diagnosis and assessment

lupus;
specific drugs

tetracyclines,
50

triamcinolone,
221,
222, 245

thalidomide,
232

tricyclic antidepressants,
179, 193, 203

therapeutic approaches to lupus: categories,

trigger fingers,
80, 81

181;
cognitive therapy,
203–4, 258;
future

Tsao, Betty,
41

of,
261–66;
immune ablative therapy,
265–

tubular dysfunction,
149